Clinical trials: Cyclophosphamide, completed
Nausea, Vomiting
A Randomized Controlled Trial to Evaluate the Efficacy of Acupuncture Versus Aromatherapy as Treatments to Lessen Nausea, Vomiting and Anxiety Associated With Adriamycin and Cytoxan
The overall goal of this study is to explore the effectiveness of using acupuncture versus aromatherapy, in conjunction with standard of care anti-emetics, to decrease chemotherapy induced nausea, vomiting, and anxiety in breast…
- Conditions
- Nausea, Vomiting, Anxiety
- Trial name
- NCT04116697
- Testing
- Acupuncture, Aromatherapy
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Englewood Hospital and Medical Center
Neuroblastoma
Combination Chemotherapy Followed by Surgery and Peripheral Stem Cell or Bone Marrow Transplantation in Treating Infants With Newly Diagnosed Neuroblastoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell or bone marrow transplantation may allow the doctor to give…
- Trial name
- NCT00025649
- Testing
- filgrastim, busulfan, carboplatin
- Where
- 11 sites in Austria, Belgium and 9 more
- Sponsor
- European Infant Neuroblastoma Study Group - 1999
Breast Cancer, Breast Neoplasm
Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer
This study will assess the usefulness of a technique called complementary deoxyribonucleic acid (cDNA) microarray-an examination of a wide array of genes to identify disease-associated patterns-for measuring tumor response to…
- Trial name
- NCT00005908
- Testing
- Docetaxel - Dose A, Anastrozole, cyclophosphamide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma
Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma
This phase I/II trial studies the side effects and best dose of carfilzomib when given together with rituximab and combination chemotherapy and to see how well they work in treating patients with diffuse large B-cell lymphoma.
- Conditions
- Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT02073097
- Testing
- Carfilzomib, Rituximab, Cyclophosphamide
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Case Comprehensive Cancer Center
Chronic Myeloproliferative Disorders, Leukemia
Clofarabine and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or Myeloproliferative Disorders
RATIONALE: Drugs used in chemotherapy, such as clofarabine and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic/Myeloproliferative Diseases
- Trial name
- NCT00293410
- Testing
- clofarabine, cyclophosphamide
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Systemic Lupus Erythematosus
Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)
The purpose of this study is to initially access the safety and effectivity of RC18 combined with standard treatment and Placebo combined with standard therapy in subjects with Moderate to severe SLE, Besides ,to provide dose…
- Trial name
- NCT02885610
- Testing
- RC18 80 mg plus standard therapy, RC18 160 mg plus standard therapy, RC18 240 mg plus standard therapy
- Where
- China
- Volunteers
- 249 people
- Sponsor
- RemeGen Co., Ltd.
Congenital Pediatric Disorders
Umbilical Cord Blood Transplant for Congenital Pediatric Disorders
The purpose of this study is to determine the safety and effectiveness of Umbilical Cord Blood Transplant (UCBT) to treat the patient's disease, and to see if this treatment can decrease the incidence of GVHD.
- Trial name
- UCB (NCT00950846)
- Testing
- Busulfan, Cytoxan, Fludarabine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Baylor College of Medicine
Neuroblastoma, Effects of Immunotherapy
Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma
Patients with refractory and/or recurrent neuroblastoma have poor prognosis despite complex multimodel therapy and therefore, novel approaches are urgently needed.
- Trial name
- 4SCAR-GD2 (NCT02765243)
- Testing
- Anti-GD2 CART
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Zhujiang Hospital
Leukemia, B-cell Leukemia
Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia
The primary objective of this study was to evaluate the safety and efficacy of the combination of fludarabine and cyclophosphamide in previously untreated CLL patients.
- Conditions
- Leukemia, B-cell Leukemia, Chronic Leukemia, Chronic Lymphocytic Leukemia (CLL)
- Trial name
- NCT00230282
- Testing
- Alemtuzumab, Fludarabine, Cytoxan
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Steven E. Coutre
Transplantation, Homologous, Transplantation, Autologous
Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG
To evaluate the toxicity and tolerability of this tandem autologous/allogeneic transplant approach for patients with advanced stage multiple myeloma.
- Conditions
- Transplantation, Homologous, Transplantation, Autologous, Multiple Myeloma, Blood and Marrow Transplant (BMT)
- Trial name
- NCT00899847
- Testing
- Autologous peripheral blood stem cells (auto-PBSC) transplantation, Allogeneic peripheral blood stem cells (allo-PBSC) transplantation, Filgrastim
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Stanford University
Breast Cancer
Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer
The primary objective of this study is to determine the safety and feasibility of combining cyclin B1/WT-1/CEF (antigen)-loaded DC vaccination with preoperative chemotherapy.
- Trial name
- NCT02018458
- Testing
- LA TNBC: DC vaccine+Preop chemo, ER+/HER2-BC:DC vaccine+Preop chemo
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Baylor Research Institute
Recurrent Melanoma, Stage IV Melanoma
Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma
This phase I trial studies the side effects and best dose of autologous T-antigen-presenting cells (T-APC) vaccine following therapeutic autologous lymphocytes (CTL) and cyclophosphamide in treating patients with metastatic…
- Trial name
- NCT01339663
- Testing
- cyclophosphamide, aldesleukin, autologous tumor cell vaccine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Fred Hutchinson Cancer Center
Sarcoma
Clinical Study of Metronomic Oral Cyclophosphamide in Patients With Advanced Sarcomas
This is a single arm phase II clinical study to evaluate the efficacy and safety of metronomic oral cyclophosphamide in elderly and/or pre-treated patients with advanced sarcomas.
- Trial name
- NCT01716689
- Testing
- oral cyclophosphamide
- Where
- Singapore
- Volunteers
- 24 people
- Sponsor
- National Cancer Centre, Singapore
Lung Cancer
Combination Chemotherapy in Treating Patients With Extensive Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003606
- Testing
- cisplatin, cyclophosphamide, epirubicin hydrochloride
- Where
- France
- Volunteers
- 216 people
- Sponsor
- UNICANCER
Lymphoma
S9911, Combination Chemotherapy Plus Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00003784
- Testing
- CHOP regimen, cyclophosphamide, doxorubicin hydrochloride
- Where
- 87 sites in United States
- Volunteers
- 102 people
- Sponsor
- SWOG Cancer Research Network
Diffuse Large B Cell Lymphoma
Rituximab, Cyclophosphamide, Vincristine and Prednisone (R-CHOP) Plus Metformin in Diffuse Large-B-cell Lymphoma
Evaluation of the safety and effectiveness of metformin as an adjunct to RCHOP chemotherapy for patients with newly diagnosed diffuse large-B cell lymphoma
- Trial name
- NCT03200015
- Testing
- Metformin
- Where
- Mexico
- Volunteers
- 15 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Peripheral T-cell Lymphomas (PTCL), PTCL-NOS
Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas
This is a multicenter study that includes two phases: 1. A phase I study to define the maximum tolerated dose (MTD) of Romidepsin in addition to CHOEP-21 and to test the safety and feasibility of CHOEP-21 in combination with dose…
- Conditions
- Peripheral T-cell Lymphomas (PTCL), PTCL-NOS, Angioimmunoblastic T-cell Lymphoma (AITL), ALK- Anaplastic Large Cell Lymphoma (ALCL)
- Trial name
- FIL_PTCL13 (NCT02223208)
- Testing
- Ro-CHOEP-21 (PHASE I), Ro-CHOEP-21 (PHASE II)
- Where
- 27 sites in Italy
- Volunteers
- 89 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Leukemia, Lymphoma
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia
RATIONALE: Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00133991
- Testing
- Filgrastim, Rituximab, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Leukemia, Multiple Myeloma
Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies
The purpose of the study is to conduct a phase I study of adoptive immunotherapy with autologous, ex-vivo expanded cytokine-induced killer (CIK) cells to reduce the relapse rate in autologous stem cell transplant patients with…
- Trial name
- NCT00477035
- Testing
- CIK cells, etoposide, bcnu
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Sally Arai
Extragonadal Germ Cell Tumor, Ovarian Cancer
Combination Chemotherapy in Treating Children With Non-testicular Malignant Germ Cell Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002489
- Testing
- dactinomycin, filgrastim, carboplatin
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.